CID-25014542

CAS No. 220904-99-4

CID-25014542( CID-25014542 | CID25014542 | CID 25014542 )

Catalog No. M17441 CAS No. 220904-99-4

CID-25014542 is novel inhibitor of Raf kinases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 39 In Stock
5MG 37 In Stock
10MG 59 In Stock
25MG 111 In Stock
50MG 165 In Stock
100MG 240 In Stock
200MG 337 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CID-25014542
  • Note
    Research use only, not for human use.
  • Brief Description
    CID-25014542 is novel inhibitor of Raf kinases.
  • Description
    CID-25014542 is novel inhibitor of Raf kinases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CID-25014542 | CID25014542 | CID 25014542
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    Raf
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    220904-99-4
  • Formula Weight
    429.49
  • Molecular Formula
    C15H8Br2ClNO2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (232.83 mM)
  • SMILES
    c1cc2c(cc1Cl)/C(=C/c1cc(c(c(c1)Br)O)Br)/C(=O)N2
  • Chemical Name
    (3Z)-5-Chloro-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-1H-indol-2-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lulli D, Carbone ML, Pastore S. The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes. Int J Mol Sci. 2017 Oct 24;18(10)
molnova catalog
related products
  • N-Desmethylclozapine

    N-Desmethylclozapine is an antagonist of serotonin (5-HT) receptor subtype 5-HT2C (IC50: 7.1 nM). It also is an antagonist at dopamine D4 receptors an agonist at δ-opioid receptors.

  • 2-Methyl-5-HT

    2-Methyl-5-HT is a potent and selective 5-HT3 receptor agonist with anti-depressive-like effects.

  • Cerlapirdine

    Cerlapirdine is a selective, potent, full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine is already in clinical development for the treatment of cognitive disorders related to Alzheimer's disease and schizophrenia. It works by acting as a selective 5-HT6 receptor antagonist.